- beta-blocker (BB)
- ca2+ blocker (CCB)
- true sympatholytic agents (e.g. alpha-blockers like phentolamine, and vasodilatory agents such as GTN, SNP, etc)
CCBs and BBs
- CVS: bradycardia, hypotension, AV block, heart failure
- CNS: lethargy, confusion, seizures, coma (generally secondary to the CVS effects)
Digoxin is also characterised by increased automaticity (e.g. PVCs, PACs and other dysrhythmias)
Propanolol causes sodium channel blockade as well as B-blocker effects
True sympatholytic agents present with vasodilation, hypotension, reflex tachycardia +/- evidence of poor perfusion
– ECG: bradycardia, PR, QRS, QT prolongation, heart blocks, asystole.
SPECIFIC MANAGEMENT AND TRIGGERS FOR INTERVENTION
- decontamination with activated charcoal and whole bowel irrigation (if risk assessment is for severe toxicity from a sustained release agent before toxicity is apparent)
- charcoal haemoperfusion in verapamil OD?
Ca2+ channel blockers and beta-blockers
- Ca2+ chloride 1-3g -> 2-6g/hr (maintain ionized Ca2+ between 2-3mmol/L)
- glucagon 5-10mg bolus -> 2-5mg/hr (traditional treatment, but not as useful as HIET)
- vasopressors and inotropes:
– isoprenaline 2mcg/min
– adrenaline 0.1-1mcg/kg/min
– noradrenaline 0.1-1mcg/kg/min
- pacing to achieve ventricular capture @ 50-80/min (often ineffective)
- high-dose insulin euglycaemic therapy (MAINSTAY of modern therapy, start early)
- lipid emulsion: may bind calcium channel blockers in plasma and prevent myocardial penetration
- extracorporeal support – intra-aortic balloon pump, VA ECMO or cardiopulmonary bypass
- supportive care (especially respiratory support)
- IV fluids
- rarely are vasopressors required
- trial naloxone (controlversial: may need high doses and has inconsistent effects)
- supportive care
- IV fluids
- vasopressors if hypoperfusion: noradrenaline
- correct Ca
- treat CN toxicity from SNP
Chris is an Intensivist and ECMO specialist at the Alfred ICU in Melbourne. He is also the Innovation Lead for the Australian Centre for Health Innovation at Alfred Health, a Clinical Adjunct Associate Professor at Monash University, and the Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Education Committee. He is a co-founder of the Australia and New Zealand Clinician Educator Network (ANZCEN) and is the Lead for the ANZCEN Clinician Educator Incubator programme. He is on the Board of Directors for the Intensive Care Foundation and is a First Part Examiner for the College of Intensive Care Medicine. He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives.
After finishing his medical degree at the University of Auckland, he continued post-graduate training in New Zealand as well as Australia’s Northern Territory, Perth and Melbourne. He has completed fellowship training in both intensive care medicine and emergency medicine, as well as post-graduate training in biochemistry, clinical toxicology, clinical epidemiology, and health professional education.
He is actively involved in in using translational simulation to improve patient care and the design of processes and systems at Alfred Health. He coordinates the Alfred ICU’s education and simulation programmes and runs the unit’s education website, INTENSIVE. He created the ‘Critically Ill Airway’ course and teaches on numerous courses around the world. He is one of the founders of the FOAM movement (Free Open-Access Medical education) and is co-creator of LITFL.com, the RAGE podcast, the Resuscitology course, and the SMACC conference.
His one great achievement is being the father of two amazing children.
On Twitter, he is @precordialthump.